GSK525762
Drug timelines are a Plus or Pro feature.
5 regulatory and trial events tracked for GSK525762, covering 2017-12-08 to 2022-01-27. Get the full timeline:
Most recent: Clinical Trial Update: Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Participants With Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced or Metastatic Breast Cancer [Phase 1]